EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY-NC 4.0

Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review

Niuniu Li, Qiang Wu, Juan Meng, Cheng Feng, Siwei Jiang, Meixia Chen, Wenhui Xu, Fei Wang, Yifan Zhang, Juncai Liu, Cheng Xu, Gaolin Liu und 1 weitere

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14431 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Niuniu Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Hepatopulmonary Syndrome, Pulmonary Arterial Hypertension, Hypertension, Pulmonary, Hypertension, Portal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen High-level Hospital Construction Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension-targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48-year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO2), cTNI, and NT-proBNP changes indicated gradual recovery, without hepatic safety concerns. This case indicated that administering macitentan in patients diagnosed as PoPH (with CLF and HPS) may be efficient and safe enough in a clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatopulmonary SyndromePulmonary Arterial HypertensionHypertension, PulmonaryHypertension, PortalHumansMalePyrimidinesSulfonamides

Stichwörter der Autor:innen

Hepatopulmonary syndromeLiver failureMacitentanPortopulmonary hypertension

Substanzen

macitentanPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Geriatric Medicine, Shenzhen Third People's Hospital, Shenzhen, China.
  • Washington University in St. Louis, St. Louis, USA.

Förderung

  • Shenzhen High-level Hospital Construction Fund

Zitieren

APA

Li, N., Wu, Q., Meng, J., Feng, C., Jiang, S., Chen, M., Xu, W., Wang, F., Zhang, Y., Liu, J., Xu, C., Liu, G., & Gao, H. (2023). Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review. ESC Heart Failure. https://doi.org/10.1002/ehf2.14431

Vancouver

Li N, Wu Q, Meng J, Feng C, Jiang S, Chen M, et al. Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review. ESC Heart Failure. 2023. doi:10.1002/ehf2.14431

BibTeX
@article{Li2023,
  author = {Li, Niuniu and Wu, Qiang and Meng, Juan and Feng, Cheng and Jiang, Siwei and Chen, Meixia and Xu, Wenhui and Wang, Fei and Zhang, Yifan and Liu, Juncai and Xu, Cheng and Liu, Gaolin and Gao, Hong},
  title = {Macitentan Treatment of Portopulmonary Hypertension with Hepatopulmonary Syndrome: A Case Report and Literature Review},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14431}
}
Kostenlos starten →